Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
 - EconoTimes)
NEW ORLEANS, Oct. 13, 2017 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 24, 2017 to file lead plaintiff applications in a securities class action lawsuit against Dr. Reddy’s Laboratories Ltd. (NYSE:RDY), if they purchased the Company’s securities between June 17, 2015 and August 10, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
What You May Do
If you purchased securities of Dr. Reddy’s and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit http://ksfcounsel.com/cases/nyse-rdy/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by October 24, 2017.
About the Lawsuit
Dr. Reddy’s and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company had failed to implement an effective corporate quality control system including but not limited to its manufacturing plants and (ii) as a result of the foregoing, Dr. Reddy’s financial statements were materially false and misleading at all relevant times.
About Kahn Swick & Foti, LLC
KSF, whose partners include the former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
206 Covington St.
Madisonville, LA 70447
